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ABSTRACT
Introduction: Whey-acidic protein human epididymis protein 4 (HE4) is a new promising biomarker for 
epithelial ovarian cancer. The measured HE4 values may depend on the testing procedure used. The aim 
of this study was to evaluate the 
Methods: We evaluated a HE4 method on Elecsys 2010 analyzer. The method for quantitative determi-
nation of HE4 is direct, competitive chemiluminescent immunoassay. For quality control we use Elecsys 
PreciControl HE4 1 and 2. HE4 was measure on sera obtained from 56 women ( 20 healthy and 36 with 
epithelial ovarian cancer). 
Results: The Roche HE4 assays showed a good linearity (r=0.99) and precision (intrassayed total CV<5%). 
The median HE4 serum concentrations was signifi cantly higher among EOC patients than healthy females 
(p<0,05). Elevated levels HE4 were found in 78 % patients with epithelial ovarian cancer. 
Conclusions: The presented results of the analytical evaluation methods for the determination of HE4 on 
the Elecsys 2010 analyzer showed an acceptable accuracy and precision.
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INTRODUCTION
Epithelial ovarian cancer (EOC) is the fourth most 
common cause of cancer mortality in women and 
the leading cause of death from gynecological ma-
lignancies. Th e majority of women have advanced-
stage disease at initial diagnosis and a 5-year survival 
of 10-30 %. Th e median survival after recurrence is 
only 2 years despite the advances in chemotherapy 
and secondary debulking surgery in selected pa-
tients (1).
Th e human epididymis protein 4 (HE4, also known 
as WFDC2) belongs to the family of whey acidic 
four-disulfi de core (WFDC) proteins with suspect-
ed trypsin inhibitor properties. Th e corresponding 
gene codes for a 13 kD protein. In its mature gly-
cosylated form the protein has a molecular weight 
of approximately 20-25 kD and consists of a single 
peptide chain containing two WFDC domains (2).
HE4 was fi rst determined in the epithelium of the 
distal epididymis. It showed low expression in epi-
thelia of respiratory and reproductive tissues includ-
ing ovary, but high expression in ovarian cancer tis-
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sue. High secreted levels can also be found in the 
serum of ovarian cancer patients (3).
Th e measured HE4 value of a patients sample can 
vary depending on the testing procedure used. Th e 
laboratory fi nding must therefore always contain a 
statement on the HE4 assay method used. HE4 val-
ues determined on patient samples by diff erent test-
ing procedures cannot be directly compared with 
one another and could be the cause of erroneous 
medical interpretations (4,5). 
Th e assay is to be used as aid in monitoring recur-
rence or progressive disease in patients with epithe-
lial ovarian cancer. Serial testing for patient HE4 as-
say values should be used in conjunction with other 
clinical methods used for monitoring ovarian cancer 
(6). 
Moore and colleagues (7) have reported that the 
serum biomarker algorithm ROMA (Risk of Ovar-
ian Malignancy Algorithm), which utilizes the dual 
marker combination of HE4 and CA125, along 
with menopause status, shows good performance for 
risk prediction of ovarian malignances (7).
METHODS
Blood samples were collected from 36 female pa-
tients with epithelial ovarian cancer (mean age: 56 
years, range 48-69 years). Control samples (N=20) 
were collected from healthy females. Th e blood was 
collected into the non-heparinized tubes and kept 
30 min at room temperature, then centrifuged for 
15 min at 3000 rpm. Th e sera were then stored at 
-20 oC until use. 
Th e serum levels of HE4 were determined using a 
chemiluminescent enzyme immunoassay on the 
Elecsys 2010 Analyzer (Roche Diagnostics, Germa-
ny) according to manufacturer, s instructions. Th e 
HE4 assay is a two-step immunoassay for quantita-
tive determination of HE4 antigen in human serum 
using CMIA technology. In the fi rst step, sample 
and 2H5 anti-HE4 coated paramagnetic micropa-
ticles are combined. HE4 antigen present in the 
sample binds to the anti-HE4 coated microparticles. 
After washing, 3D8 anti-HE4 acridinium-lebeled 
conjugate is added to create a reaction mixture 
in the second step. Following another wash cycle, 
pre-trigger and trigger solutions are added to the 
reaction mixture. Th e resulting chemiluminiescent 
reaction is measured as relative light units (RLUs). 
A direct relationship exists between the amount of 
HE4 antigen in the sample and RLUs. 
For quality control ElecsysPreciControl HE4 1 and 
2 (Roche Diagnostics, Germany) were used.
Statistical analysis
Th e data were analyzed in SPSS version 18 (Chicago, 
IL, USA). Descriptive statistics and Pearson correla-
tion were used. Th e diff erence between groups were 
considered signifi cant if p<0.05.
RESULTS
Th e results of the HE4 assay precision within-run 
and between-run analyses are showed in Table 1.
Th e coeffi  cients of variation (CV%) values for the 
within-run precision were 6.9 – 8.2 %, with those 
for between-run ranging 7.9 – 9.8%. Th e results 
variation was greater at lower concentrations.
Th e HE4 assay accuracy results are presented in 
Table 2.
Th e statistically signifi cant correlation between 
labeled and measured HE4 values was obtained 
(r=0.99), presented by the following equation: y= 
-1.20+0.99x, where y represents the measured HE4 
levels, and x labeled HE4 levels. An intercept (-1.20) 
presents the systematic errors of the method, which 
was not statistically signifi cant (p>0.05). 
Sample Sample Mean value Sd CV(%)
value (n) (pmol/L) (pmol/L) 
Within-run
PreciControl HE4 1 20 45.5 3.7 8.2
PreciControl HE4 2 20 341.5 23.5 6.9
Between-run
PreciControl HE4 1 20 42.4 4.1 9.8
PreciControl HE4 2 20 347.7 29.2 7.9
Calibrators (pmol/L) 20.0 50.0 100.0 500.0 1000.0
Measured values* 
(pmol/L) 29.7 49.2 98.4 497.1 992.1
TABLE 1.  Within-run and between-run precision of HE4 as-
say
TABLE 2.  Accuracy of HE4 assay on Elecsys 2010 analyzer.
*Mean of two measurements of calibrators
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Serum samples were collected from 36 ovarian can-
cer patients (EOC). Results of HE4 measurements 
in diff erent groups are shown in Table 3.
Th e median serum HE4 concentrations were sig-
nifi cantly higher among all ovarian cancer patients 
compared with group of healthy subjects.
Patients with ovarian carcinoma showed signifi cant-
ly higher HE4 levels of 139.6 (range: 34.2 – 1383.0) 
pmol/L compared to healthy controls levels of 32.1 
(range: 11.2 – 72.3) pmol/L. In the present study, 
signifi cantly elevated HE4 concentrations were 
found in 28 of 36 cases of ovarian cancer, and cut off  
levels of 74 pmol/L gave the sensitivity rate of 78%. 
DISCUSSION
Human Epididymis Protein 4 (HE4) is a 25 KD 
single peptide chain with a low expression in epithe-
lia of repertory and reproductive tissues, but highly 
expressed in ovarian cancer tissue. HE4 is a novel 
serological marker used especially for ovarian cancer 
diagnosis because of its high sensitivity (8). Th e per-
centage of increase in HE4 values has been used as 
an aid in monitoring recurrence or progressive dis-
ease in patients with invasive epithelial ovarian can-
cer. Th ere is no clinically accepted cut-off  for use in 
monitoring cancer progression in epithelial ovarian 
cancer (9). Currently, several biomarker panels are 
being evaluated in increase the sensitivity and speci-
fi city of ovarian cancer diagnosis. Th e combination 
of CA125 and HE4 has been evaluated to improve 
ovarian cancer diagnosis. Th e data suggests that by 
combining these markers the predictive accuracy in 
ovarian malignancy is better than by applying any 
of the markers alone (10). As a single tumor marker, 
HE4 had the highest sensitivity for detecting ovar-
ian cancer, especially in stage I disease.
Th e analysis of HE4 by competitive chemilumines-
cent immunoassay on Elecsys 2010 analyser is rapid 
and easy to perform. Th e linearity range of assay is 
from 20 to 1000 pmol/L, which is acceptable for 
routine clinical use. Th e CV for precision in this as-
say is not greater than 10% at the lowest measurable 
concentration. Th e obtained CV% values for preci-
sion were for the within-run precision were 6.9 – 8.2 
%, with those for between-run ranging 7.9 – 9.8%. 
Th e results variation was greater at lower concentra-
tions.
Th e median concentrations in women test group 
were 139.6 (range 34,2 – 1383,0 ) pmol/L. Refer-
ence interval for HE4 ranges between 0 to 74. Th e 
median serum HE4 concentrations were signifi cant-
ly higher among all ovarian cancer patients com-
pared with group of healthy subjects. Elevated levels 
HE4 were found in 78 % patients with epithelial 
ovarian cancer. 
CONCLUSION
Early detection is a critical focus of ovarian cancer 
research because of its potential to reduce suff ering 
and morbidity. HE4 assay values obtained with dif-
ferent assay methods cannot be used interchange-
ably due to diff erences in assay methods and reagent 
specifi city. Th e results reported by the physician 
must include the identity of the HE4 assay used. 
Th e presented results of the analytical evaluation 
methods for the determination of HE4 on Elecsys 
2010 analyzer showed an acceptable accuracy and 
precision. 
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